SG11201903076QA - Carbamoyl phenylalaninol compounds and uses therof - Google Patents
Carbamoyl phenylalaninol compounds and uses therofInfo
- Publication number
- SG11201903076QA SG11201903076QA SG11201903076QA SG11201903076QA SG11201903076QA SG 11201903076Q A SG11201903076Q A SG 11201903076QA SG 11201903076Q A SG11201903076Q A SG 11201903076QA SG 11201903076Q A SG11201903076Q A SG 11201903076QA SG 11201903076Q A SG11201903076Q A SG 11201903076QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- pct
- english
- october
- unless
- Prior art date
Links
- NJVZDURTFWBXAM-VIFPVBQESA-N [(2S)-1-hydroxy-3-phenylpropan-2-yl]urea Chemical class C(N)(=O)N[C@@H](CC1=CC=CC=C1)CO NJVZDURTFWBXAM-VIFPVBQESA-N 0.000 title abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 235000020004 porter Nutrition 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/62—Compounds containing any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylcarbamates
- C07C271/66—Y being a hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/46—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylureas
- C07C275/58—Y being a hetero atom
- C07C275/60—Y being an oxygen atom, e.g. allophanic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Rheumatology (AREA)
- Nutrition Science (AREA)
- Addiction (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662404917P | 2016-10-06 | 2016-10-06 | |
| PCT/US2017/055598 WO2018067971A1 (en) | 2016-10-06 | 2017-10-06 | Carbamoyl phenylalaninol compounds and uses therof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201903076QA true SG11201903076QA (en) | 2019-05-30 |
Family
ID=60183122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201903076QA SG11201903076QA (en) | 2016-10-06 | 2017-10-06 | Carbamoyl phenylalaninol compounds and uses therof |
Country Status (11)
| Country | Link |
|---|---|
| US (5) | US10710958B2 (https=) |
| EP (2) | EP3523275B1 (https=) |
| JP (1) | JP7074750B2 (https=) |
| KR (1) | KR102616545B1 (https=) |
| CN (1) | CN110049966A (https=) |
| CA (1) | CA3039045A1 (https=) |
| ES (1) | ES2964943T3 (https=) |
| MY (1) | MY202185A (https=) |
| PH (1) | PH12019500751A1 (https=) |
| SG (1) | SG11201903076QA (https=) |
| WO (1) | WO2018067971A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11400065B2 (en) | 2019-03-01 | 2022-08-02 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12478604B1 (en) | 2016-07-22 | 2025-11-25 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12186296B1 (en) | 2016-07-22 | 2025-01-07 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| JP7366002B2 (ja) | 2017-07-31 | 2023-10-20 | ジャズ ファーマシューティカルズ アイルランド リミテッド | カルバモイルフェニルアラニノール類縁体およびその使用 |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100197892B1 (ko) | 1994-09-09 | 1999-06-15 | 남창우 | 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법 |
| KR0173862B1 (ko) | 1995-02-11 | 1999-04-01 | 조규향 | O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법 |
| US5756817C1 (en) | 1995-02-11 | 2001-04-17 | Sk Corp | O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same |
| KR0173863B1 (ko) | 1995-04-10 | 1999-04-01 | 조규향 | 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법 |
| DK1140061T3 (da) | 1998-12-23 | 2003-08-25 | Orphan Medical Inc | Mikrobiologisk sunde og stabile opløsninger af gamma-hydroxybutyratsalt til behandling af narcolepsi |
| US6680322B2 (en) | 1999-12-02 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
| US6680324B2 (en) | 2000-12-01 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
| US6680299B2 (en) | 2001-07-27 | 2004-01-20 | Enanta Pharmaceuticals, Inc. | 4'-substituted leucomycins |
| RU2007119648A (ru) | 2004-10-28 | 2008-12-10 | СК Холдингз Ко. | Способ лечения депрессии |
| EP1890684B1 (en) | 2005-06-08 | 2013-08-14 | SK Biopharmaceuticals Co., Ltd. | Treatment of sleep-wake disorders |
| ES2344469T3 (es) | 2005-06-22 | 2010-08-27 | Sk Holdings Co., Ltd. | Tratamiento de disfuncion sexual. |
| KR20120098578A (ko) | 2009-06-22 | 2012-09-05 | 에스케이바이오팜 주식회사 | 피로의 치료 또는 예방 방법 |
| US8232315B2 (en) | 2009-06-26 | 2012-07-31 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating drug addiction and improving addiction-related behavior |
| EP2496227B1 (en) * | 2009-11-06 | 2019-05-22 | SK Biopharmaceuticals Co., Ltd. | Methods for treating fibromyalgia syndrome |
| BR112012010670A2 (pt) | 2009-11-06 | 2016-04-12 | Sk Biopharmaceuticals Co Ltd | métodos para tratamento de distúrbio de défict de atenção/hiperatividade |
| US8623913B2 (en) | 2010-06-30 | 2014-01-07 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating restless legs syndrome |
| US9610274B2 (en) | 2010-06-30 | 2017-04-04 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating bipolar disorder |
| US9050302B2 (en) | 2013-03-01 | 2015-06-09 | Jazz Pharmaceuticals Ireland Limited | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
| CA2905457A1 (en) * | 2013-03-13 | 2014-10-09 | Aerial Biopharma, Llc | Treatment of cataplexy |
| JP2016530240A (ja) | 2013-07-12 | 2016-09-29 | ジャズ ファーマスティカルズ インターナショナル スリー リミテッドＪａｚｚ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｉｉ Ｌｉｍｉｔｅｄ | 禁煙の促進 |
| CA2917702A1 (en) * | 2013-07-18 | 2015-01-22 | Jazz Pharmaceuticals International Iii Limited | Treatment for obesity |
| TWI698415B (zh) | 2014-02-28 | 2020-07-11 | 南韓商愛思開生物製藥股份有限公司 | 胺基羰基胺基甲酸酯化合物 |
| US10888542B2 (en) | 2014-02-28 | 2021-01-12 | Sk Biopharmaceuticals Co., Ltd. | Aminocarbonylcarbamate compounds |
-
2017
- 2017-10-06 ES ES17790906T patent/ES2964943T3/es active Active
- 2017-10-06 MY MYPI2019001915A patent/MY202185A/en unknown
- 2017-10-06 KR KR1020197013113A patent/KR102616545B1/ko active Active
- 2017-10-06 CN CN201780075629.4A patent/CN110049966A/zh active Pending
- 2017-10-06 SG SG11201903076QA patent/SG11201903076QA/en unknown
- 2017-10-06 JP JP2019518480A patent/JP7074750B2/ja active Active
- 2017-10-06 WO PCT/US2017/055598 patent/WO2018067971A1/en not_active Ceased
- 2017-10-06 EP EP17790906.6A patent/EP3523275B1/en active Active
- 2017-10-06 EP EP23199791.7A patent/EP4316592A3/en active Pending
- 2017-10-06 US US16/338,925 patent/US10710958B2/en active Active
- 2017-10-06 CA CA3039045A patent/CA3039045A1/en not_active Abandoned
-
2019
- 2019-04-05 PH PH12019500751A patent/PH12019500751A1/en unknown
-
2020
- 2020-06-03 US US16/891,464 patent/US11149000B2/en active Active
-
2021
- 2021-09-09 US US17/470,063 patent/US11780805B2/en active Active
-
2023
- 2023-09-18 US US18/469,032 patent/US20240018098A1/en not_active Abandoned
-
2024
- 2024-11-05 US US18/937,105 patent/US20250059136A1/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11400065B2 (en) | 2019-03-01 | 2022-08-02 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
| US12167992B2 (en) | 2019-03-01 | 2024-12-17 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
Also Published As
| Publication number | Publication date |
|---|---|
| US11149000B2 (en) | 2021-10-19 |
| ES2964943T3 (es) | 2024-04-10 |
| US20190218175A1 (en) | 2019-07-18 |
| PH12019500751A1 (en) | 2019-08-05 |
| CA3039045A1 (en) | 2018-04-12 |
| EP3523275A1 (en) | 2019-08-14 |
| US20220098145A1 (en) | 2022-03-31 |
| WO2018067971A1 (en) | 2018-04-12 |
| US11780805B2 (en) | 2023-10-10 |
| CN110049966A (zh) | 2019-07-23 |
| KR102616545B1 (ko) | 2023-12-26 |
| EP4316592A3 (en) | 2024-05-01 |
| US10710958B2 (en) | 2020-07-14 |
| US20200290955A1 (en) | 2020-09-17 |
| MY202185A (en) | 2024-04-15 |
| JP2020503246A (ja) | 2020-01-30 |
| EP4316592A2 (en) | 2024-02-07 |
| KR20190072561A (ko) | 2019-06-25 |
| US20240018098A1 (en) | 2024-01-18 |
| US20250059136A1 (en) | 2025-02-20 |
| JP7074750B2 (ja) | 2022-05-24 |
| EP3523275B1 (en) | 2023-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201903076QA (en) | Carbamoyl phenylalaninol compounds and uses therof | |
| SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
| SG11201909963YA (en) | Methods for treating dravet syndrome | |
| SG11201804915RA (en) | Methods for treating huntington's disease | |
| SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
| SG11201907034PA (en) | Methods of treating influenza | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201804758QA (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
| SG11201901986SA (en) | Process for the manufacture of a solid pharmaceutical adminstration form | |
| SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
| SG11201909807TA (en) | Methods of manufacturing of niraparib | |
| SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
| SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
| SG11201809830WA (en) | Selective reduction of cysteine-engineered antibodies | |
| SG11201906313SA (en) | A polypeptide linker for preparing multispecific antibodies | |
| SG11201900361RA (en) | Methods of treating prostate cancer | |
| SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11201809708PA (en) | Physiologically balanced injectable formulations of fosnetupitant | |
| SG11201807062RA (en) | Anti-tnfalpha-antibodies and functional fragments thereof | |
| SG11201901048VA (en) | Pharmaceutical compositions and uses directed to lysosomal storage disorders |